Liminatus Pharma, Inc. Class A Common Stock (LIMN) stock price, financials & research

Regular session · ET · Market data may be delayed.

GoAI snapshot

Jul 10, 2026

39/ 100

GoAI Score

Sell

Valuation

60

Fair Value

Sentiment

51

Mixed

Risk

66

High Risk

Momentum

17

Strong Down

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

Company profile

Company website

Liminatus Pharma, Inc. is an immuno-oncology firm, currently in its clinical development phase, dedicated to pioneering new treatments for cancer. The company's headquarters are located in La Palma, California.

Industry: Biotechnology
Sector: Healthcare
Headquarters: US
CEO: Chris Kim
Listed since: May 1, 2025
Employees: 1

Market position

Day range

Current $3.6845

$3.60$3.95

52-week range

Current $3.6845

$3.29$141.5

Open: $3.95
Previous close: $3.88
Volume: 35.94K; 0.07× average
Average volume: 493.05K; Average daily volume
Market cap: 4.95M USD
Beta: 0.74; Market reference 1
50-day average: $4.5522; -19.06% below average
200-day average: $13.9098; -73.51% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value: 15.59M USD
P/E (TTM): -0.16×
P/B (TTM): 5.82×
P/S (TTM): 0×
EV / EBITDA: -1.56×
Earnings yield: -70.44%
Free cash flow yield: -68.85%
Dividend yield: 0.00%

Profitability & efficiency

Gross margin: 0.00%
Operating margin: 0.00%
Net margin: 0.00%
Return on equity: 103.99%
Return on assets: -1990.37%
Return on invested capital: 35.57%

Financial health

Debt / equity: 4.8×
Current ratio: 0.05×
Altman Z-score: -28
Piotroski F-score: 2 of 9

Financial statements

Income trends

Operating income

−2.97M USD-2.12%

Net income

−10.21M USD-251.43%

Financial statements: Income statement
Metric (USD)	FY2025	FY2024	FY2023	FY2022	FY2021
Research and development	—	2.69M USD	3.76M USD	1.85M USD	3.8M USD
Selling, general, and administrative	2.97M USD	645K USD	1.06M USD	856K USD	197K USD
Operating expenses	2.97M USD	2.91M USD	2.59M USD	2.71M USD	2.53M USD
Interest income	76.59K USD	137.72K USD	10K USD	—	16.84K USD
Interest expense	215.9K USD	138.1K USD	175K USD	219K USD	—
Depreciation and amortization	1.83K USD	—	—	1K USD	—
Operating income	−2.97M USD	−2.91M USD	−2.59M USD	−2.71M USD	−2.53M USD
Net income	−10.21M USD	−2.9M USD	−1.23M USD	−2.93M USD	4.37M USD

Company facts updated Oct 8, 2026.

Earnings

Latest EPS result: -1.5

EPS: actual versus estimate

Recent quarterly results

ActualEstimate

Estimates unavailable

LIMN news

globenewswire.comSep 29, 2026

Liminatus Pharma Regains Compliance with Nasdaq Minimum Bid Price Rule

FULLERTON, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (Nasdaq: LIMN) (“Liminatus” or the “Company”) today announced that the Company has regained compliance with Nasdaq's minimum bid price rule.

Read source

globenewswire.comAug 24, 2026

Liminatus Pharma Engages Synex as Contract Research Organization to Support Phase 1/2a Clinical Development of CD19xCD22 bivalent CAR-T therapy

FULLERTON, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (Nasdaq: LIMN) (“Liminatus” or the “Company”), a biotechnology company developing innovative cancer therapies, today announced that it has…

Read source

globenewswire.comAug 18, 2026

Liminatus Pharma, Inc. Announces Reverse Stock Split of its Common Stock

FULLERTON, Calif., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (Nasdaq: LIMN) (“Liminatus” or the “Company”) today announced that its board of directors has adopted resolutions approving a reverse stock…

Read source

globenewswire.comAug 13, 2026

Liminatus Pharma Announces Transfer to Nasdaq Capital Market and Extension to Regain Compliance with Minimum Bid Price Requirement

FULLERTON, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (Nasdaq: LIMN) (“Liminatus” or the “Company”), a biopharmaceutical company developing novel therapies for cancer and other serious diseases,…

Read source

Corporate actions

Corporate action history

Action	Effective date	Details	Record date	Payment date
Stock split	Aug 21, 2026	1:50	—	—

Stock split

Effective Aug 21, 2026

1:50

LIMN peers

AMGN

Amgen Inc.

$405.95

-1.73%

GILD

Gilead Sciences, Inc.

$146.09

-0.52%

ISRG

Intuitive Surgical, Inc.

$415.38

+0.21%

VRTX

Vertex Pharmaceuticals Incorporated

$505.21

-0.09%

SNY

Sanofi

$40.0924

-0.27%

MRNA

Moderna, Inc.

$194.79

-0.86%

ETFs holding LIMN

Funds reporting this stock among their holdings, ordered by reported position size.

ETFMarket valueWeightAUMExpense ratioPrice / 1D

Vanguard Extended Market ETFVXF3.89K—95.4B USD0.05%$232.3-0.51%

Vanguard Extended Market ETFVXF

Market value: 3.89K
Weight: —
AUM: 95.4B USD
Expense ratio: 0.05%
Price / 1D: $232.3-0.51%

Liminatus Pharma, Inc. Class A Common Stock

LIMN company overview

Company profile

Liminatus Pharma, Inc. Class A Common Stock

LIMN company overview

GoAI snapshot

Company profile

Market position

Financials

Financial snapshot

Valuation & yield

Profitability & efficiency

Financial health

Financial statements

Income trends

Earnings

EPS: actual versus estimate

LIMN news

Liminatus Pharma Regains Compliance with Nasdaq Minimum Bid Price Rule

Liminatus Pharma Engages Synex as Contract Research Organization to Support Phase 1/2a Clinical Development of CD19xCD22 bivalent CAR-T therapy

Liminatus Pharma, Inc. Announces Reverse Stock Split of its Common Stock

Liminatus Pharma Announces Transfer to Nasdaq Capital Market and Extension to Regain Compliance with Minimum Bid Price Requirement

Corporate actions

Corporate action history

LIMN peers

ETFs holding LIMN

Continue in GoAI

LIMN company overview

Company profile

Market position

LIMN company overview

Company profile

LIMN company overview

Company profile

Market position

LIMN company overview

GoAI snapshot

Company profile

Market position

Financials

Financial snapshot

Valuation & yield

Profitability & efficiency

Financial health

Financial statements

Income trends

Earnings

EPS: actual versus estimate

LIMN news

Liminatus Pharma Regains Compliance with Nasdaq Minimum Bid Price Rule

Liminatus Pharma Engages Synex as Contract Research Organization to Support Phase 1/2a Clinical Development of CD19xCD22 bivalent CAR-T therapy

Liminatus Pharma, Inc. Announces Reverse Stock Split of its Common Stock

Liminatus Pharma Announces Transfer to Nasdaq Capital Market and Extension to Regain Compliance with Minimum Bid Price Requirement

Corporate actions

Corporate action history

LIMN peers

ETFs holding LIMN

Continue in GoAI